Acceptance and practicability of a visual communication tool in smoking cessation counselling: a randomised controlled trial by Neuner-Jehle, Stefan et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2013
Acceptance and practicability of a visual communication tool in smoking
cessation counselling: a randomised controlled trial
Neuner-Jehle, Stefan; Knecht, Marianne I; Stey-Steurer, Claudia; Senn, Oliver
Abstract: BACKGROUND: Smoking cessation advice is important for reducing the worldwide burden
of disease resulting from tobacco smoking. Appropriate risk communication formats improve the success
of counselling interventions in primary care. AIMS: To test the feasibility and acceptance of a smoking
cessation counselling tool with different cardiovascular risk communication formats including graphs, in
comparison with the International Primary Care Respiratory Group (IPCRG) ’quit smoking assistance’
tool. METHODS: GPs were randomised into an intervention group (using our communication tool in
addition to the IPCRG sheet) and a control group (using the IPCRG sheet only). We asked partici-
pants for socioeconomic data, smoking patterns, understanding of information, motivation, acceptance
and feasibility, and measured the duration and frequency of counselling sessions. RESULTS: Twenty-five
GPs performed 2.8 counselling sessions per month in the intervention group and 1.7 in the control group
(p=0.3) with 114 patients. The median duration of a session was 10 mins (control group 11 mins, p=0.09
for difference). Median patients’ motivation for smoking cessation was 7 on a 10-point visual analogue
scale with no significant difference before and after the intervention (p=0.2) or between groups (p=0.73
before and p=0.15 after the intervention). Median patients’ ratings of motivation, selfconfidence, under-
standing of information, and satisfaction with the counselling were 3-5 on a 5-point Likert scale, similar
to GPs’ ratings of acceptance and feasibility, with no significant difference between groups. CONCLU-
SIONS: Among Swiss GPs and patients, both our innovative communication tool and the IPCRG tool
were well accepted and both merit further dissemination and application in research.
DOI: 10.4104/pcrj.2013.00086
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-93640
Published Version
Originally published at:
Neuner-Jehle, Stefan; Knecht, Marianne I; Stey-Steurer, Claudia; Senn, Oliver (2013). Acceptance and
practicability of a visual communication tool in smoking cessation counselling: a randomised controlled
trial. Primary Care Respiratory Journal, 22(4):412-416. DOI: 10.4104/pcrj.2013.00086
Prim Care Respir J 2013; 22(4): 412-416
RESEARCH PAPER
Acceptance and practicability of a visual communication
tool in smoking cessation counselling: a randomised
controlled trial
*Stefan Neuner-Jehle1,4, Marianne I Knecht1, Claudia Stey-Steurer1,2,3, Oliver Senn1,2
1 Institute of General Practice and Health Services Research, University of Zürich, Switzerland
2 Medical Practice, Zürich, Switzerland
3  Medix HMO, Switzerland
4  Medical Practice, Zug, Switzerland
Originally received 22nd March 2013; resubmitted 18th June 2013; revised 3rd July 2013; further revision 5th July 2013; accepted 5th July 2013; 
online 7th October 2013
Abstract
Background: Smoking cessation advice is important for reducing the worldwide burden of disease resulting from tobacco smoking.
Appropriate risk communication formats improve the success of counselling interventions in primary care.
Aims: To test the feasibility and acceptance of a smoking cessation counselling tool with different cardiovascular risk communication
formats including graphs, in comparison with the International Primary Care Respiratory Group (IPCRG) ‘quit smoking assistance’ tool.
Methods: GPs were randomised into an intervention group (using our communication tool in addition to the IPCRG sheet) and a control
group (using the IPCRG sheet only). We asked participants for socioeconomic data, smoking patterns, understanding of information,
motivation, acceptance and feasibility, and measured the duration and frequency of counselling sessions.
Results: Twenty-five GPs performed 2.8 counselling sessions per month in the intervention group and 1.7 in the control group (p=0.3)
with 114 patients. The median duration of a session was 10 mins (control group 11 mins, p=0.09 for difference). Median patients’
motivation for smoking cessation was 7 on a 10-point visual analogue scale with no significant difference before and after the
intervention (p=0.2) or between groups (p=0.73 before and p=0.15 after the intervention). Median patients’ ratings of motivation, self-
confidence, understanding of information, and satisfaction with the counselling were 3–5 on a 5-point Likert scale, similar to GPs' ratings
of acceptance and feasibility, with no significant difference between groups. 
Conclusions: Among Swiss GPs and patients, both our innovative communication tool and the IPCRG tool were well accepted and both
merit further dissemination and application in research. 
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Introduction 
Tobacco smoking is a significant public health problem. About half
of all persistent cigarette smokers are killed by their habit – a quarter
while still in middle age – with an estimated mortality worldwide of
5,000,000 per year.1-4 According to the World Health Organization,
smoking is the leading preventable cause of death worldwide.3
Compared with non-smokers, the relative risk of a smoker developing
cardiovascular disease (CVD) is 1.6–3.0, of suffering a stroke is 1.8–4.8,
and of developing lung or oropharyngeal cancer is 17.8–22.3,
dependent on age and gender.1 However, the incidence (absolute risk)
of malignant disease due to smoking is considerably lower than that of
CVD as a potential long-term consequence of smoking. 
See linked editorial by Lewis on pg 387
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In a recent survey in Switzerland the proportion of smokers in
the population was 27%, similar to the last decade.5 Half of the
smokers who consider quitting are either in a contemplation state
or in a preparation state according to the transtheoretical model
(TTM) of changing behaviour.5,6 In this process of reconsidering,
motivation and self-efficacy are independent predictors of success.7
As the majority of Swiss smokers (84%) discussed smoking
cessation issues with their general practitioners (GPs),5 GPs are
important key players in the effort to reduce the proportion of
smokers in a population. A short smoking cessation intervention
from the GP based on the individual smoker’s motivational state
helps patients to quit8 and is therefore an important and relevant
method of reducing the hazards associated with smoking.
In patient counselling, communication tools (particularly visual
aids) and motivational interviewing techniques improve the success
of interventions aimed at behaviour change.9-12 We therefore
developed a smoking cessation counselling tool which integrates
visual aids and facilitates motivational interviewing techniques.
Based on the International Primary Care Respiratory Group (IPCRG)
‘quit smoking assistance’ tool and the counselling process,13 we
added some relevant risk information about smoking. To translate
CVD risks, we used a combination of communication formats
(verbal, numerical, visual) and focused on the benefits to the patient
(risk reduction) of smoking cessation. The IPCRG tool was used as
the reference standard and we hypothesised that our tool is not
inferior to the IPCRG tool with regard to feasibility and acceptance.  
Methods 
Development of the tool: choice of outcome (risk) to
communicate   
We chose CVD morbidity as the main risk communication issue for
our tool in order to achieve maximal motivation. We calculated the
absolute 10-year risk for cardiovascular events for smokers aged
35–65 years versus non-smokers of the same age using the risk
calculator of the Swiss Task Force on Lipids and Atherosclerosis
(www.agla.ch),14 which uses the database of the PROCAM cohort.15
Risk calculation by this tool requires age, gender, menopausal state,
total serum cholesterol, serum HDL, serum triglycerides, diabetes,
and family history. Our intention was to perform the counselling tool
as a short intervention and as time-sparingly as possible. On the
other hand, we wanted to perform individualised counselling based
on the individual risk situation of each patient. Therefore, in order to
avoid time-consuming data sampling from patients, we assumed
gender-specific average values for most of the required
cardiovascular risk factors based on the representative population-
based Swiss cohort study SAPALDIA.16 Thus, GPs only had to define
gender, age, and smoking state of the patients to assess the
individualised cardiovascular risk, which was possible to do within a
few seconds (see Appendix 1, available online at www.thepcrj.org). 
In our tool, risks are shown numerically with absolute
percentages, relative percentages and natural frequencies, and
visually with colour-coded bar charts (see Appendix 2, available
online at www.thepcrj.org). Additionally, the age-related
cardiovascular risk of a smoker is communicated in relation to the
age of a non-smoker with the equivalent risk (organ age risk
communication format, analogous to the lung age concept12). In
order to standardise the ‘usual’ counselling interventions for
tobacco smoking cessation, all participating GPs used the
recommended Opinion Sheet for smoking cessation of the IPCRG13
(see Appendix 3, available online at www.thepcrj.org) which is using
motivational interviewing techniques. 
Study protocol    
The 27 participating GPs were randomised into an intervention
group using our communication tool in addition to the IPCRG sheet,
and a control group using the IPCRG sheet only. All study GPs
underwent a group instruction. After a run-in period of two months
to assess the frequency of usual counselling activity, the study period
was six months. In each practice the GPs included up to 10
consecutive smokers aged 20–80 years. Exclusion criteria were a
short life expectancy (<10 years), cognitive impairment, or any acute
disease. 
Characteristic Median IQR Number % of 
cases
Physician characteristics 
(n=27*)                                      
Age, years 48 43-55
Experience as a GP, years 10 4-19
Workload, percentage 
(100%=5 days working/week) 100 60-100
Sex, males 14 52.9
Practice type, solo 9 33.3
No. of patients counselled 
per GP 4 2-7
Patient characteristics 
(n=114)
Age, years 47 33-57
Sex, male 60 50.9
Education level, primary 12 10.2
secondary 67 56.8
high school 11 9.3
academic 28 23.7
Age at the begin of smoking, 
years 17 15-20
Duration of smoking, years 29 15-38
Cigarettes per day 1-5 4 3.4
6-10 23 19.5
11-15 18 15.3
16-20 39 33.1
21-25 18 15.3
>25 16 13.6
No attempts to quit 74 64.4
Partner smoking (n with 
partner=67) 31 46.3
*Two GPs did not perform any counselling session.
Table 1. Baseline characteristics
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Measurements   
Patient data on socioeconomics, smoking history, smoking patterns,
comprehensiveness of the information, satisfaction, self-confidence,
acceptance, and feasibility were collected by a questionnaire using a
5-point Likert scale. Patients rated their motivation before and after
the intervention on a 10-point numerical visual analogue scale (VAS).
GPs measured counselling duration and frequency as a proxy for
acceptance and were asked about their estimates of acceptance and
practicability of the tool by a short questionnaire. 
Statistics   
We defined a difference in counselling frequency between the
intervention and control groups of ≤20% as suggesting non-
inferiority of the tool compared with usual care. Data are presented
as median (IQR) and frequencies. Patient and counselling
characteristics were compared between the intervention and control
groups using Wilcoxon tests. In addition, a modified Wilcoxon rank
sum test17 was applied to account for the potential cluster
dependence at the GP level. A two-sided alpha level of 0.05 was
assumed to indicate significance. The analyses were performed
using Stata® Version 12.1 (Stata Corporation, College Station, Texas,
USA; www.stata.com).
All patients gave written informed consent and the study was
approved by the local ethics committee of Zurich.
Results
The characteristics of the GPs and patients are shown in Table 1. On
average (medians), GPs had 10 years’ practice experience; two-thirds
of them were working in group practices. The average patient had
been a smoker since the age of 17 and for almost 30 years. One-third
of patients had not tried to quit smoking before and half of the
patients had partners who smoked. The prevalence of comorbidities
in our study population was equal to the average Swiss practice
population (data not shown). 
Detailed group comparisons of counselling and tool
characteristics are shown in Table 2. During the 6-month study
period, 25 GPs performed 2.8 (IQR 1.7–4.2) counselling sessions per
month in the intervention group and 1.7 (IQR 1.3–3.3) in the control
group (p=0.3), with a total of 114 patients. Compared with the run-
in period, fewer counselling sessions were performed in both groups
(43.1% fewer in the intervention group and 40.0% fewer in the
control group), resulting in a median (IQR) difference in change
between the groups of –1.6% (–39.7% to 40.0%), p=1.0; Table 2).
The median duration of a counselling session was similar in both
groups (10 mins in the intervention group and 11 mins in the control
group, p=0.09); 51% of counselling sessions took less than 10 mins.
GPs’ ratings on practicability and usefulness were high for both tools
(median of 4 on a 5-point Likert scale in the intervention group and
3 in the control group, p=0.13 and p=0.55, respectively). Patients’
motivation for smoking cessation was already high before the
intervention (median 7 on a 10-point VAS) with no significant
difference after the intervention (p=0.20) or between groups
(p=0.73 and p=0.15 before and after the intervention, respectively).
Patients’ ratings of the increase in motivation, self-confidence,
comprehensiveness of the information, and satisfaction with the
Counselling and tool characteristics Intervention Control
Median (IQR) Median (IQR) p Value
Number of counselling sessions, per month 2.8 (1.7-4.2) 1.7 (1.3-3.3) 0.30
Number of counselling sessions in the run-in study period, per month 5.5 (2.3-6.0) 4.0 (2.5-6.0) 0.72
Change in number of counselling sessions from the run-in period to 
study period, per month –1.9 (?3.2;0.3) –1.3 (–2.7;0.5) 0.74
Change in number of counselling sessions from the run-in period to
study period, % –43.1 (–55.6;17.4) –40.0 (–62.5;20.4) 1.00
Duration of counseling sessions, min 10 (7-12) 11 (8-17) 0.09
*Practicability, rated by GP 4 (3-4) 3 (2-4) 0.13
*Usefulness, rated by GP 4 (3-4) 3 (2-4) 0.55
†Patients’ motivation for smoking cessation, rated by patients:     
Before intervention 7 (5-8) 7 (5-8) 0.73
After intervention 7 (5-8) 7 (5-9) 0.15
Difference before and after intervention 0 (0-0) 0 (0-1) 0.20
*Patients’ increase in motivation, rated by patients 4 (3-4) 4 (3-5) 0.26
*Self-confidence, rated by patients 3 (3-4) 4 (3-4) 0.42
*Understanding of information 5 (4-5) 5 (5-5) 0.35
*Satisfaction with counselling 5 (4-5) 5 (5-5) 0.57
*Understanding of the tool 4 (4-5) -
*Patients’ increase in motivation by the tool, rated by patients 4 (3-4) -
*Five-point Likert scale from 1 (denied) to 5 (highly approved). 
†VAS from 1 (“I don’t want to quit smoking at all”) to 10 (“I want to quit smoking by all means”).
Table 2. Comparisons of counselling and tool characteristics between groups. Results are based on 25 GPs (15
controls) and 114 counselling sessions (67 controls)
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counselling were generally high (medians 3–5 on a 5-point Likert
scale). In clustered data group comparisons using Wilcoxon rank
sum tests, counselling time and patient ratings remained unchanged
between groups (data not shown). With regard to the visual
intervention tool, comprehensiveness and increase in motivation for
smoking cessation due to the tool were both rated highly (medians
of 4 on a 5-point Likert scale). 
Discussion
Main findings 
Our main finding is that adding a visual tool with a pictorial risk
message as proposed by our group is not inferior to the usual
smoking cessation IPCRG tool in terms of acceptance and feasibility.
In fact, the majority of GPs rated both counselling tools as equally
practicable and useful. No significant differences were seen between
the intervention and control groups with regard to the patients’
estimates of increased motivation, self-confidence,
comprehensiveness of the information, and satisfaction. 
Most of the counselling activities with the pictorial intervention
tool were performed within 10 mins, with no significant difference in
the duration of counselling compared with the control group. This
underlines the feasibility of the tool, fulfilling the criteria of a short-
term intervention. 
The motivation level for smoking cessation was surprisingly high
(median 7 points on a 10-point VAS), which could partially be due to
selection bias at the patient level. The increase in motivation resulting
from the counselling was not consistent: the item about self-
estimated increase of motivation was mostly answered positively
whereas the VAS measurement before and after counselling did not
show a significant difference. A possible explanation is the short time
between the two measurements: change of motivation as a basis for
change of behaviour is often an iterative process over a long period.
It is important to note that neither of the two communication tools
decreased motivation in patients. 
The decrease in counselling frequency during the study period
compared with the run-in period is difficult to explain. Feedback from
the study GPs suggests two main reasons: (1) a recall effect (the
longer time since the instruction was given, the less alert were GPs
about recruiting patients); and (2) many study GPs claimed a higher
work load and lack of time during the study period in comparison
with the run-in period. However, the decrease in counselling
frequency was not significantly different between the intervention
and control groups, so our tool was not the cause for less counselling
activity. 
Because a sharpened awareness of developing CVD can function
as a strong motivator for behaviour change,18 the concept of how to
communicate individualised risks for smokers versus non-smokers is
highly relevant for fostering smoking cessation. We chose to
communicate cardiovascular risks visually rather than respiratory risks
because the absolute CVD risks (incidence) are higher than the
respiratory risks, reflecting an even higher impact of the total burden
of smoking-associated diseases on a patient as well as at the
population level. Furthermore, the systemic effects of smoking do not
only affect the respiratory system, but also the cardiovascular and
other symptoms. The epidemiological evidence linking chronic
obstructive pulmonary disease (COPD), for example, and
cardiovascular morbidity and mortality is strong: patients with COPD
have a 2–3-fold increase in the risk of cardiovascular events including
death.19 In individuals with severe airways obstruction (forced
expiratory volume in one second (FEV1) <50% of predicted), the
leading causes of death are cardiovascular in nature.20 For every 10%
decrease in FEV1, cardiovascular mortality increases by about 28%
and non-fatal coronary events increase by about 20% in patients
with mild to moderate COPD.21
In our tool we emphasise the communication of relative risks
(known to enhance the motivation to avoid risk11) and present it
numerically and visually. To minimise the risk of manipulation of
patients with the risk format, we combined information about
relative risk with data on the absolute risk of a smoker. In order to
facilitate decisions, we offer a comparison with a healthy (non-
smoking) reference subject. The communication of the organ (heart)
age of a current smoker versus a non-smoker is another way of
creating motivation by comparison of two options.12 Thus, using risk
communication at the state of the art level9-12 results in positive effects
in smoking cessation.
While calculating the relative risks of smokers versus non-smokers
in the age group 35–65 years based on the data of a middle
European cohort (PROCAM),15 we found an identical relative risk of 2
(or nearly 2) as reported from other calculators based on the
Framingham cohort. Recently, the SCORE risk charts22 – which are
also based on the Framingham cohort – started to communicate this
relative risk of smokers versus non-smokers in addition to information
on the absolute 10-year risk of a lethal cardiovascular event in the
charts.   
Strengths and limitations of this study         
To our knowledge, this is the first randomised controlled trial (RCT)
using the IPCRG smoking cessation tool as a ‘usual care’ standard.
Moreover, the tool we developed is innovative and integrative in
putting modern and evidence-based risk communication
recommendations into daily practice.9-12
Our study took place in one single region of Switzerland and with
a relatively small number of GPs, so the results are not generalisable
without restrictions. Most of our outcomes were self-estimates and
not clinical outcomes, as we had neither the intention nor the means
to do a RCT of the clinical effects of the intervention but, rather,
wanted to test our approach and its acceptance and feasibility. As the
focus of the current study was the feasibility and acceptability of the
novel counselling tool, a proper a priori sample size calculation was
not possible due to the lack of reliable a priori assumptions. However,
based on the 114 counselling sessions in our study, there was 80%
power to detect a minimal one-sided difference of 23% (alpha
level=0.05), which almost meets the a priori non-inferiority level
postulated to be clinically relevant (difference of >20%). 
We cannot exclude a selection bias due to the recruitment
procedure of GPs and patients. GPs with a higher motivation for
counselling activities in the field of smoking cessation might have
been more prone to agree to participate and patients willing to
participate might have been more motivated to start counselling than
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those who declined to participate. The high ratings of motivation
(preparation stage of the TTM model) for a change at baseline might
be an indicator of a possible bias. However, there was no significant
difference between the intervention and control groups. We think
the possible selection bias has only a small – if any – impact on our
acceptance and feasibility results.
Interpretation of findings in relation to previously
published work          
Our findings encourage the use of both instruments in smoking
cessation counselling. The IPCRG tool seems to be a well-accepted and
feasible tool for short-term intervention smoking cessation counselling
in Swiss primary care and merits further dissemination. Our additional
tool fostering visual risk communication in order to increase motivation
of smokers to quit is equally well accepted and feasible and might be
an important add-on to the IPCRG tool. 
The high level of acceptance of our tool may be due to the mixed
communication formats we used – especially the focus on relative
risks and visual elements – both of which were preferred by general
practice patients.11 With regard to efficacy, the additional use of
information about organ age (in our tool, heart age) is a promising
way to encourage smoking cessation. Parkes et al. demonstrated an
absolute difference in quit rate of 7.2% (13.6% in the intervention
group versus 6.4% in the control group) using a similar lung age
communication tool.12
Implications for future research, policy and practice     
Considering the immense impact of smoking cessation on patients’
health and healthcare resources, it is of utmost importance to support
and optimise smoking cessation counselling in primary care. Based on
our results, we plan to carry out a RCT to test whether our visual risk
communication tool has an additional effect on smoking cessation
rates compared with the usual short intervention counselling, and
whether the combination of our pictorial tool with the IPCRG tool is
superior to the IPCRG tool alone.  
Conclusions   
In Swiss primary care, the feasibility and acceptability of both our
visual smoking cessation communication tool and the IPCRG tool
were equally high. Both merit further dissemination and clinical use
as well as application in research. 
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Appendix 1. Communication aid for GPs: Calculation of absolute risks and organ age in smokers versus non-smokers
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Appendix 2. Visually supported risk communication tool (intervention tool)
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Appendix 3. IPCRG Opinion sheet for stop smoking (in english)
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Appendix 4. VISTO pilot study - CONSORT 2010 checklist of information to include when reporting a randomised
trial*
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Appendix 4. VISTO pilot study - CONSORT 2010 checklist of information to include when reporting a randomised
trial* continued
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